A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. A cross sectional study’ – a correspondence

Xue-Lei Li, Zhi-Peng Liu, Hai-Su Dai, Xian-Yu Yin, Zhi-Yu Chen · 2023

Read A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. A cross sectional study’ – a correspondence by Xue-Lei Li, Zhi-Peng Liu, Hai-Su Dai, Xian-Yu Yin, Zhi-Yu Chen (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10720794.txt.

Description

Xue-Lei Li and co-authors write to question a study that favored chemotherapy before surgery for removable pancreatic cancer, in a 2023 correspondence. The study compared patients who received chemotherapy first against those operated on immediately, and reported better survival for the chemotherapy-first group. The letter writers accept the finding's importance but raise a confound the authors overlooked.

Nearly every chemotherapy-first patient went on to receive post-surgery drug therapy, while only about half of the surgery-first group did. Since that follow-up therapy itself extends survival, the comparison cannot show whether the benefit came from the early chemotherapy or from more total therapy. They suggest re-analysis with both groups' follow-up treatment held consistent. A second point concerns the rates of complete tumor removal between the groups. The letter is offered as a constructive correction to a clinically important comparison.

Catalog record

CREATORXue-Lei Li, Zhi-Peng Liu, Hai-Su Dai, Xian-Yu Yin, Zhi-Yu Chen
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE4 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10720794

Browse the full library · About the Tower of Babel